13.04

0.46% -0.075

Syndax Pharmaceuticals Inc (SNDX)

Overview News Price History Option Chain Financials Discussions Forecast

Syndax Pharmaceuticals Inc stock is traded at $13.04, with a volume of 157.20K. It is down -0.46% in the last 24 hours and down -13.40% over the past month. Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Previous Close:

$13.12

Open:

$13.18

24h Volume:

157.20K

Relative Volume:

0.07

Market Cap:

$1.14B

Revenue:

$139.71M

Net Income/Loss:

$-209.36M

P/E Ratio:

-4.4071

EPS:

-2.96

Net Cash Flow:

$-160.60M

1W Performance:

-8.61%

1M Performance:

-13.40%

6M Performance:

-31.69%

1Y Performance:

-45.03%

1-Day Range:

$13.04

$13.53

1-Week Range:

$12.26

$14.39

52-Week Range:

$12.06

$25.07

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name

Syndax Pharmaceuticals Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

781-419-1400

Address

35 GATEHOUSE DRIVE, WALTHAM, MA

Employee

184

Twitter

@syndax

Next Earnings Date

2025-03-03

Latest SEC Filings

SNDX's Discussions on Twitter

Compare SNDX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SNDX Syndax Pharmaceuticals Inc	13.04	1.14B	139.71M	-209.36M	-160.60M	-2.96
VRTX Vertex Pharmaceuticals Inc	500.85	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	682.70	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	577.77	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.17	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.50	26.76B	3.32B	-860.46M	-1.04B	-8.32

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-24-24	Initiated	UBS	Buy
Jun-28-24	Initiated	Jefferies	Buy
Jan-31-24	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Dec-22-23	Initiated	Mizuho	Buy
Oct-25-23	Initiated	BofA Securities	Buy
Oct-11-23	Initiated	Goldman	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jul-11-23	Initiated	Guggenheim	Buy
Apr-17-23	Resumed	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jan-03-23	Initiated	JP Morgan	Overweight
Jul-28-22	Resumed	B. Riley Securities	Buy
Apr-11-22	Initiated	H.C. Wainwright	Buy
Feb-15-22	Initiated	Goldman	Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
May-25-21	Initiated	Citigroup	Buy
Feb-18-21	Initiated	B. Riley Securities	Buy
Dec-03-20	Initiated	Stifel	Buy
May-22-20	Upgrade	Citigroup	Neutral → Buy
May-22-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-18-20	Downgrade	Citigroup	Buy → Neutral
May-11-20	Reiterated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Overweight
Jan-13-20	Reiterated	H.C. Wainwright	Buy
Mar-08-19	Reiterated	H.C. Wainwright	Buy
Jan-04-19	Initiated	Robert W. Baird	Outperform
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy
Mar-16-17	Initiated	FBR & Co.	Outperform
Mar-02-17	Initiated	Instinet	Buy
Oct-07-16	Initiated	Guggenheim	Buy
Mar-28-16	Initiated	Citigroup	Buy
Mar-28-16	Initiated	JMP Securities	Mkt Outperform
Mar-28-16	Initiated	Morgan Stanley	Overweight

View All

Syndax Pharmaceuticals Inc Stock (SNDX) Latest News

02:40 AM

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

02:40 AM

Mar 12, 2025

Syndax Pharmaceuticals’ SWOT analysis: stock soars on FDA approvals, faces profitability hurdles - Investing.com India

Mar 12, 2025

Graft Versus Host Disease Market Expected to rise, 2034 | Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio - The Globe and Mail

Mar 12, 2025

Candriam S.C.A. Cuts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Mar 12, 2025

Mar 11, 2025

What Does Syndax Pharmaceuticals Inc’s (NASDAQ: SNDX) Future Hold? - Stocks Register

Mar 11, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 7.4% Following Weak Earnings - MarketBeat

Mar 09, 2025

Mar 08, 2025

JPMorgan Chase & Co. Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat

Mar 08, 2025

Citigroup Issues Pessimistic Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat

Mar 08, 2025

Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Mar 08, 2025

Syndax Pharmaceuticals Reports 2024 Financial Results - MSN

Mar 08, 2025

Mar 07, 2025

Syndax Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

What is B. Riley’s Estimate for SNDX Q3 Earnings? - Defense World

Mar 07, 2025

What is HC Wainwright’s Forecast for SNDX FY2025 Earnings? - Defense World

Mar 07, 2025

Mar 06, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Quarterly Earnings Results - MarketBeat

Mar 06, 2025

Strong Buy Rating for Syndax Pharmaceuticals Driven by Revuforj’s Market Potential and Revenue Growth - TipRanks

Mar 06, 2025

HC Wainwright Reiterates “Buy” Rating for Syndax Pharmaceuticals (NASDAQ:SNDX) - Defense World

Mar 06, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World

Mar 06, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Earnings Results, Misses Expectations By $0.79 EPS - MarketBeat

Mar 06, 2025

Syndax Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 06, 2025

What is B. Riley’s Forecast for SNDX Q1 Earnings? - Defense World

Mar 06, 2025

What is HC Wainwright’s Forecast for SNDX Q1 Earnings? - Defense World

Mar 06, 2025

Mar 05, 2025